233 related articles for article (PubMed ID: 26113896)
1. Fetal nuchal translucency scan in Nigeria.
Oloyede OA; Abbey M; Oloyede AA; Nwachukwu O
Pan Afr Med J; 2014; 18():62. PubMed ID: 26113896
[TBL] [Abstract][Full Text] [Related]
2. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
3. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
4. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
5. Prospective audit of a one-centre combined nuchal translucency and triple test programme for the detection of trisomy 21.
Babbur V; Lees CC; Goodburn SF; Morris N; Breeze AC; Hackett GA
Prenat Diagn; 2005 Jun; 25(6):465-9. PubMed ID: 15966036
[TBL] [Abstract][Full Text] [Related]
6. Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
[TBL] [Abstract][Full Text] [Related]
7. First trimester risk assessment for trisomy 21 in twin pregnancies combining nuchal translucency and first trimester biochemical markers.
Prats P; Rodríguez I; Comas C; Puerto B
Prenat Diagn; 2012 Oct; 32(10):927-32. PubMed ID: 22752980
[TBL] [Abstract][Full Text] [Related]
8. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of increased nuchal translucency as a screening test for the detection of fetal chromosomal abnormalities.
Alexioy E; Alexioy E; Trakakis E; Kassanos D; Farmakidis G; Kondylios A; Laggas D; Salamalekis E; Florentin L; Kanavakis E; Basios G; Trompoukis P; Georgiadoy L; Panagiotopoulos T
J Matern Fetal Neonatal Med; 2009 Oct; 22(10):857-62. PubMed ID: 19521928
[TBL] [Abstract][Full Text] [Related]
10. Comparison of first-trimester contingent screening strategies for Down syndrome.
Sahota DS; Leung TY; Chan LW; Law LW; Fung TY; Chen M; Lau TK
Ultrasound Obstet Gynecol; 2010 Mar; 35(3):286-91. PubMed ID: 20052660
[TBL] [Abstract][Full Text] [Related]
11. Screening for fetal chromosomal abnormalities with nuchal translucency measurement in the first trimester.
Has R; Kalelioglu I; Ermis H; Ibrahimoglu L; Yuksel A; Yildirim A; Basaran S
Fetal Diagn Ther; 2006; 21(4):355-9. PubMed ID: 16757911
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and outcome of increased nuchal translucency in usmanu danfodiyo university teaching hospital, Sokoto, Nigeria: A cohort study.
Sulaiman B; Shehu CE; Panti AA; Saidu SA; Onankpa B; Ekele BA
Niger J Clin Pract; 2020 Jun; 23(6):864-869. PubMed ID: 32525124
[TBL] [Abstract][Full Text] [Related]
13. Screening for Down syndrome based on maternal age or fetal nuchal translucency: a randomized controlled trial in 39,572 pregnancies.
Saltvedt S; Almström H; Kublickas M; Valentin L; Bottinga R; Bui TH; Cederholm M; Conner P; Dannberg B; Malcus P; Marsk A; Grunewald C
Ultrasound Obstet Gynecol; 2005 Jun; 25(6):537-45. PubMed ID: 15912479
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA analysis for noninvasive examination of trisomy.
Norton ME; Jacobsson B; Swamy GK; Laurent LC; Ranzini AC; Brar H; Tomlinson MW; Pereira L; Spitz JL; Hollemon D; Cuckle H; Musci TJ; Wapner RJ
N Engl J Med; 2015 Apr; 372(17):1589-97. PubMed ID: 25830321
[TBL] [Abstract][Full Text] [Related]
15. First-trimester ultrasonographic screening for trisomy 21 using fetal nuchal translucency and nasal bone.
Sepulveda W; Wong AE; Dezerega V
Obstet Gynecol; 2007 May; 109(5):1040-5. PubMed ID: 17470580
[TBL] [Abstract][Full Text] [Related]
16. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
17. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation.
Pandya PP; Snijders RJ; Johnson SP; De Lourdes Brizot M; Nicolaides KH
Br J Obstet Gynaecol; 1995 Dec; 102(12):957-62. PubMed ID: 8652486
[TBL] [Abstract][Full Text] [Related]
18. Comparison of combined, biochemical and nuchal translucency screening for Down syndrome in first trimester in Northern Finland.
Peuhkurinen S; Laitinen P; Honkasalo T; Ryynanen M; Marttala J
Acta Obstet Gynecol Scand; 2013 Jul; 92(7):769-74. PubMed ID: 23369035
[TBL] [Abstract][Full Text] [Related]
19. Population screening for fetal trisomy 21: easy access to screening should be balanced against a uniform ultrasound protocol.
Gyselaers WJ; Vereecken AJ; Van Herck EJ; Straetmans DP; de Jonge ET; Ombelet WU; Nijhuis JG
Prenat Diagn; 2005 Nov; 25(11):984-90. PubMed ID: 16240322
[TBL] [Abstract][Full Text] [Related]
20. First trimester fetal nuchal translucency: problems with screening the general population. 2.
Bewley S; Roberts LJ; Mackinson AM; Rodeck CH
Br J Obstet Gynaecol; 1995 May; 102(5):386-8. PubMed ID: 7612532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
